Spots Global Cancer Trial Database for cd123
Every month we try and update this database with for cd123 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | NCT04156256 | Hematologic Mal... Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Myeloid... | CD123-CD33 cCAR... | - | iCell Gene Therapeutics | |
| A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies | NCT02937103 | Leukemia | Anti-CD123-CAR-... | 14 Years - 75 Years | Southwest Hospital, China | |
| Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT | NCT03114670 | Adult Acute Mye... | CD123CAR-41BB-C... | 18 Years - | Affiliated Hospital to Academy of Military Medical Sciences | |
| IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia | NCT04599543 | Acute Myeloid L... | IL3 CAR T-cells | - | Zhejiang University | |
| IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia | NCT04599543 | Acute Myeloid L... | IL3 CAR T-cells | - | Zhejiang University | |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies | NCT03125577 | B-cell Malignan... | 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... | 6 Months - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| Post-transplant Flotetuzumab for AML | NCT05506956 | Leukemia, Myelo... | Flotetuzumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY | NCT02992860 | Myelodysplastic... Acute Myeloid L... | JNJ-56022473 Bone marrow ana... Flow cytometry ... Central biobank... Histopathology ... Cytogenetic ana... Serum chemistry Automated CBC Pregnancy Test | 18 Years - | GWT-TUD GmbH | |
| Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT | NCT03114670 | Adult Acute Mye... | CD123CAR-41BB-C... | 18 Years - | Affiliated Hospital to Academy of Military Medical Sciences | |
| Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | NCT03386513 | Blastic Plasmac... Myeloproliferat... | IMGN632 | 18 Years - | ImmunoGen, Inc. | |
| Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia | NCT04272125 | Leukemia Leukemia, Myelo... Leukemia, Myelo... | CD123 CAR-T cel... | 3 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies | NCT02937103 | Leukemia | Anti-CD123-CAR-... | 14 Years - 75 Years | Southwest Hospital, China | |
| Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia | NCT04272125 | Leukemia Leukemia, Myelo... Leukemia, Myelo... | CD123 CAR-T cel... | 3 Years - 75 Years | Chongqing Precision Biotech Co., Ltd |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
